{"gene":"FGFR3","run_date":"2026-06-09T23:54:43","timeline":{"discoveries":[{"year":1995,"finding":"A missense mutation Ala391Glu in the FGFR3 transmembrane domain was identified in Crouzon syndrome with acanthosis nigricans, demonstrating that transmembrane domain mutations in FGFR3 can cause non-skeletal (skin) disorders in addition to dwarfing conditions, and revealing pleiotropic effects of FGFR3 mutations.","method":"Mutation analysis / DNA sequencing in unrelated patient families","journal":"Nature genetics","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — mutation identified in multiple unrelated families, single method (sequencing), no in vitro functional reconstitution","pmids":["7493034"],"is_preprint":false},{"year":1999,"finding":"The G375C (human)/G369C (mouse) substitution in the FGFR3 transmembrane domain causes ligand-independent dimerization and phosphorylation of FGFR3 in cells, leading to achondroplasia-like dwarfism in mice with expanded resting zone, narrowed proliferating and hypertrophic zones in growth plates, activation of Stat proteins, upregulation of cell-cycle inhibitors, increased osteoclast activity, and upregulation of osteoblast differentiation genes.","method":"Biochemical assay (dimerization, phosphorylation), mouse genetic model (knock-in), histological and molecular analysis of growth plate","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — in vitro biochemical demonstration of ligand-independent dimerization and phosphorylation plus knock-in mouse model with multiple orthogonal readouts","pmids":["10587515"],"is_preprint":false},{"year":2000,"finding":"Constitutively active FGFR3 (K650E activation loop mutation, TDII-like) phosphorylates Shp2, PLC-gamma, and MAPK, activates Stat1 and Stat3, stimulates PI3-kinase activity, transforms NIH3T3 cells, and induces neurite outgrowth in PC12 cells, defining downstream effectors of FGFR3 kinase activation.","method":"In vitro kinase/signaling assays, NIH3T3 transformation assay, PC12 neurite outgrowth assay, Western blot for downstream effectors","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal signaling assays and functional transformation assays in one study with activated mutant","pmids":["10918587"],"is_preprint":false},{"year":2000,"finding":"Stable expression of constitutively active FGFR3Ach (G380R) in CFK2 chondrocytic cells severely inhibits proliferation and prevents differentiation, induces abnormal apoptosis upon serum deprivation, and alters integrin subunit expression leading to a switch in substrate preference from fibronectin to type II collagen, providing a cellular mechanism for FGFR3-mediated inhibition of chondrocyte proliferation.","method":"Stable transfection of chondrocytic cell line, proliferation assays, differentiation assays, apoptosis assays, integrin expression analysis","journal":"Journal of bone and mineral research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — defined cellular phenotypes with multiple readouts in a single lab using constitutively active mutant","pmids":["10646125"],"is_preprint":false},{"year":2003,"finding":"Fgfr3 marks astrocytes and their neuroepithelial precursors in the developing CNS, and FGFR3 signaling normally represses GFAP expression in grey matter (protoplasmic) astrocytes, as demonstrated by strong upregulation of GFAP in grey matter astrocytes of Fgfr3-null mice.","method":"Fgfr3 knockout mouse analysis, in vitro and in vivo immunostaining, cell co-expression analysis","journal":"Development (Cambridge, England)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic loss-of-function with specific molecular readout (GFAP upregulation), single lab","pmids":["12441294"],"is_preprint":false},{"year":2005,"finding":"FGFR3 mutations and Ras gene mutations are mutually exclusive in urothelial cell carcinoma (UCC), indicating that FGFR3 activating mutations and Ras mutations represent alternative means to activate the MAPK pathway and confer the same oncogenic phenotype.","method":"Mutation screening of 98 bladder tumours and 31 cell lines for FGFR3, HRAS, NRAS, and KRAS2 mutations; statistical mutual exclusivity analysis","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — large sample genetic epistasis analysis demonstrating mutual exclusivity as pathway evidence, single method","pmids":["15897885"],"is_preprint":false},{"year":2007,"finding":"FGFR3 intracellular domain mutations (but not extracellular or transmembrane domain mutations) induce premature tyrosine phosphorylation of the receptor in the Golgi apparatus and inhibit receptor glycosylation, suggesting that premature kinase activation prevents glycosylation and leads to elevated Golgi-associated signaling.","method":"HEK cell transfection with various FGFR3 mutants, Western blotting for phosphorylation and glycosylation state","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple FGFR3 mutants tested in cell culture with orthogonal readouts (phosphorylation and glycosylation), single lab","pmids":["17320202"],"is_preprint":false},{"year":2008,"finding":"FGFR3 and MAPK signaling in chondrocytes promote synchondrosis closure and fusion of ossification centers; chondrocyte-specific activation of Fgfr3 in mice induced premature synchondrosis closure, enhanced osteoblast differentiation around synchondroses, increased Bmp ligand mRNA expression, and decreased Bmp antagonist mRNA expression in a MAPK-dependent manner.","method":"Mouse genetic models (chondrocyte-specific Fgfr3 activation), histology, gene expression analysis","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — tissue-specific genetic activation with multiple orthogonal readouts (histology, gene expression, BMP pathway changes), clear pathway placement","pmids":["18923003"],"is_preprint":false},{"year":2008,"finding":"FGFR3 (and FGFR4) do not mediate the principal renal effects of FGF23: ablation of FGFR3 alone or together with FGFR4 failed to correct hypophosphatemia or restore 1,25(OH)2D in Hyp mice, while FGFR1 co-localizes with Klotho in distal tubule, suggesting FGFR1 as the primary mediator of FGF23 renal effects.","method":"Genetic knockout (Fgfr3-null, Fgfr4-null) crossed with Hyp mouse model, serum phosphate and 1,25(OH)2D measurements, immunohistochemistry","journal":"Journal of the American Society of Nephrology : JASN","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo genetic loss-of-function with physiological readouts, negative result for FGFR3 as FGF23 receptor is itself mechanistically informative","pmids":["18753255"],"is_preprint":false},{"year":2009,"finding":"FGFR3 activation by FGF1 ligand in multiple myeloma KMS11 cells induces phosphorylation of tandem tyrosines in the kinase domain activation loop; mass spectrometry identified 52 proteins with pY sites sensitive to the FGFR3 inhibitor PD173074, including Syndecan-1/CD138, defining the FGFR3 phosphotyrosine signaling network.","method":"Label-free quantitative phosphoproteomic mass spectrometry, FGFR3 inhibitor treatment, pervanadate stimulation","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Moderate — systematic phosphoproteomic approach with inhibitor validation, identifies activation loop phosphorylation and network substrates in a disease-relevant cell line","pmids":["19901323"],"is_preprint":false},{"year":2011,"finding":"FGFR3 is internalized by both clathrin-dependent and clathrin-independent/dynamin-independent mechanisms, unlike FGFR1 which relies predominantly on clathrin-mediated endocytosis; clathrin depletion only partially inhibits FGFR3 internalization and has minimal effect on FGFR3 degradation and signaling duration.","method":"Clathrin depletion, dominant-negative dynamin mutants, live-cell imaging, signaling assays (Western blot), comparison with FGFR1","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple perturbation approaches (clathrin depletion, dominant-negative dynamin, multiple proposed endocytic regulators) with functional readouts and mechanistic comparison","pmids":["21779335"],"is_preprint":false},{"year":2011,"finding":"FGFR3 G380R (achondroplasia) transmembrane domain mutation causes the mutant receptor to form heterodimers with wild-type FGFR3 at lower probability than wild-type homodimers at low ligand concentrations, as demonstrated using a kinase-dead truncated FGFR3 construct that depletes the active receptor pool.","method":"Cell-based dimerization assay using truncated kinase-dead FGFR3 construct, phosphorylation assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — designed dominant-negative approach with quantitative phosphorylation readout, single lab","pmids":["21324899"],"is_preprint":false},{"year":2012,"finding":"FGFR3 gain-of-function mutations cause abnormal membranous ossification in addition to endochondral ossification defects in achondroplasia: Fgfr3(Y367C/+) mice exhibit partial premature fusion of coronal sutures and non-ossified gaps in frontal bones, demonstrating that FGFR3 signaling affects both endochondral and membranous bone formation.","method":"Fgfr3(Y367C/+) knock-in mouse model, craniofacial morphological analysis, comparison with human ACH patient imaging","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic model with morphological readout, corroborated by patient data, single lab","pmids":["24419316"],"is_preprint":false},{"year":2012,"finding":"Activating Fgfr3 mutation (Y367C) in chondrocytes affects trabecular bone formation via a paracrine mechanism during growth: the bone formation defect (reduced trabecular bone volume and thickness, increased osteoclast recruitment, defective osteoblast mineralization) is only observed when the mutation is expressed in cartilage (not in mature osteoblasts), and primary osteoblast proliferation/differentiation is not directly affected by Fgfr3 activation.","method":"Three mouse models expressing Fgfr3(Y367C/+) ubiquitously, chondrocyte-specific, or osteoblast-specific; histomorphometry, osteoclast and osteoblast activity assays","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — three tissue-specific genetic models with multiple quantitative readouts clearly establishing paracrine (not direct osteoblast) mechanism","pmids":["22367969"],"is_preprint":false},{"year":2012,"finding":"A 12-amino-acid peptide (P3: VSPPLTLGQLLS) identified by phage display binds specifically to the extracellular domain of FGFR3, inhibits FGFR3 tyrosine kinase activity and ERK/MAPK downstream signaling, promotes chondrogenic differentiation of ATDC5 cells, and reverses neonatal lethality and bone growth retardation in TDII mice.","method":"Phage display library screening with FGFR3 as bait, in vitro kinase inhibition assay, chondrogenic cell differentiation assay, mouse model (TDII) rescue experiment","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 1 / Strong — phage display identification, in vitro kinase assay, cell differentiation assay, and in vivo rescue experiment in disease model, multiple orthogonal methods","pmids":["23014564"],"is_preprint":false},{"year":2013,"finding":"The FGFR3-TACC3 fusion gene (from tandem duplication on 4p16.3) generates an oncogenic protein in glioblastoma that is tumorigenic, while wild-type FGFR3 overexpression is not; the fusion escapes miR-99a regulation via 3'-UTR deletion and promotes cell proliferation and tumor progression.","method":"Whole transcriptome sequencing, cell culture proliferation assays, mouse xenograft model, miRNA binding analysis","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — functional comparison of fusion vs. wild-type FGFR3, in vitro and in vivo xenograft experiments, miRNA regulation mechanism, multiple orthogonal methods","pmids":["23298836"],"is_preprint":false},{"year":2014,"finding":"FGFR3 promotes degradation of BMP type I receptor (BMPR1a) through Smurf1-mediated ubiquitination, thereby inhibiting BMP signaling and chondrogenic differentiation; chondrocyte-specific deletion of Bmpr1a rescues the bone overgrowth in Fgfr3-deficient mice; this BMPR1a degradation occurs independently of FGFR3 tyrosine kinase activity.","method":"Genetic rescue (chondrocyte-specific Bmpr1a knockout in Fgfr3-null mice), in vitro chondrogenic differentiation assays, Smad phosphorylation assays, ubiquitination assay, mouse growth plate analysis","journal":"Biochimica et biophysica acta","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis rescue experiment plus mechanistic biochemical assays (ubiquitination, Smad phosphorylation) in multiple experimental systems","pmids":["24657641"],"is_preprint":false},{"year":2014,"finding":"Statin treatment corrects degraded cartilage formation in iPSC-derived chondrocytes from thanatophoric dysplasia type I and achondroplasia patients, and rescues bone growth in ACH model mice, demonstrating that statins can pharmacologically counteract FGFR3 gain-of-function skeletal dysplasia phenotypes.","method":"Patient-specific iPSC differentiation to chondrocytes, ACH mouse model treatment, histological and molecular analysis","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — human iPSC disease model plus mouse model with functional bone growth readout, novel therapeutic mechanism established","pmids":["25231866"],"is_preprint":false},{"year":2015,"finding":"The FGFR3 juxtamembrane (JM) domain stabilizes unliganded FGFR3 dimers in the membrane through receptor-receptor contacts; this stabilization is additive with the contribution of a pathogenic TM domain mutation, and requires the JM domain to be linked to the FGFR3 TM domain (not merely membrane-anchored).","method":"Quantitative FRET-based dimerization assay in cell membranes, deletion/chimeric constructs","journal":"Journal of molecular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct biophysical measurement of dimer stability in membranes using FRET, single lab, multiple domain constructs","pmids":["25688803"],"is_preprint":false},{"year":2015,"finding":"FGFR3 deficiency in chondrocytes leads to formation of chondroma-like lesions (enchondromas and osteochondromas) via decreased ERK activity and upregulation of Indian hedgehog (IHH) signaling; MEK inhibition increases Ihh expression, and IHH signaling inhibitor treatment reduces chondroma-like lesion occurrence in Fgfr3-deficient mice.","method":"Postnatal chondrocyte-specific Fgfr3 deletion mouse model, ERK activity assay, gene expression analysis, pharmacological rescue with IHH inhibitor and MEK inhibitor","journal":"PLoS genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO with pharmacological epistasis rescue experiments establishing FGFR3→ERK→IHH pathway in chondrogenesis","pmids":["26091072"],"is_preprint":false},{"year":2016,"finding":"The FGFR3-TACC3 fusion protein is constitutively phosphorylated at key activating FGFR3 tyrosine residues (shown by TiO2-LC-MS/MS phosphopeptide enrichment); the TACC3 coiled-coil domain drives constitutive phosphorylation and increased MAPK activation, cellular transformation, and IL3-independent proliferation; FGFR3 kinase activity (not TACC3 phospho-tyrosines) is essential for oncogenic effects; nuclear localization is driven by the TACC3 domain independently of kinase activity.","method":"TiO2-LC-MS/MS phosphopeptide analysis, kinase-dead K508R mutant, domain deletion constructs, NIH3T3 transformation assay, Ba/F3 IL3-independence assay, nuclear localization imaging","journal":"Molecular cancer research : MCR","confidence":"High","confidence_rationale":"Tier 1 / Strong — mass spectrometry phosphoproteomics with mutagenesis, multiple functional assays, and localization experiments in one study","pmids":["26869289"],"is_preprint":false},{"year":2018,"finding":"The FGFR3-TACC3 (F3-T3) fusion activates oxidative phosphorylation and mitochondrial biogenesis in cancer cells; F3-T3 phosphorylates the phosphopeptide PIN4 as an intermediate step, which triggers peroxisome biogenesis and new protein synthesis; this converges on PGC1α through production of intracellular reactive oxygen species, enabling mitochondrial respiration and tumor growth.","method":"Transcriptional clustering analysis, metabolic assays (oxidative phosphorylation), ROS measurements, phosphoproteomics (PIN4 phosphorylation), peroxisome biogenesis assays, PGC1α activity assays, sensitivity to oxidative metabolism inhibitors","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal metabolic and biochemical assays in human tumors and cell lines identifying a novel signaling axis (F3-T3→PIN4→peroxisome→ROS→PGC1α→mitochondria)","pmids":["29323298"],"is_preprint":false},{"year":2018,"finding":"FGFR3 S249C mutation in urothelium suppresses acute inflammatory response (neutrophil influx) at early tumor initiation stages in response to the carcinogen OH-BBN, thereby promoting bladder tumor development; early neutrophil depletion phenocopies the FGFR3 mutation effect on later inflammatory and tumorigenic outcomes.","method":"Genetically engineered mice expressing FGFR3 S249C or K644E in urothelium, carcinogen treatment (OH-BBN), neutrophil depletion with anti-Ly6G antibody, histological and inflammatory analysis at multiple timepoints","journal":"The Journal of pathology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic model with pharmacological epistasis (neutrophil depletion), multiple timepoints, single lab","pmids":["30043421"],"is_preprint":false},{"year":2019,"finding":"FGFR3 signaling induces a MAPK/ERK-mediated increase in ETV5 transcription factor levels, which in turn elevates TAZ (a Hippo pathway co-transcriptional regulator), causing loss of contact-inhibition of proliferation; ETV5 knockdown in FGFR3-mutant bladder cancer cells reduces proliferation and anchorage-independent growth.","method":"FGFR3 inhibition/activation in bladder cancer cell lines, siRNA knockdown of ETV5, Western blot for ETV5 and TAZ levels, proliferation and anchorage-independent growth assays, MAPK pathway analysis","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pathway epistasis via knockdown with functional readouts establishing FGFR3→ERK→ETV5→TAZ axis, single lab","pmids":["30952872"],"is_preprint":false},{"year":2019,"finding":"FGFR3 signaling via the BMPR1a pathway promotes lymphatic endothelial cell (LEC) formation; FGFR3 deficiency in LECs leads to decreased lymphangiogenesis through a BMPR1a-pSmad1/5-dependent mechanism, exacerbating local inflammation and heterotopic ossification after trauma.","method":"Conditional Fgfr3 knockout in Col2+ cells and Prox1+ LECs, lineage tracing, HO mouse model (Achilles tenotomy), signaling analysis (pSmad1/5), FGF9 local administration rescue","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple conditional KO and lineage tracing approaches with pathway-level signaling readout, single lab","pmids":["34282140"],"is_preprint":false},{"year":2020,"finding":"FGFR3Δ7-9 splice variant (lacking exons 7-9) directly interacts with and phosphorylates TET2 at Y1902, leading to ubiquitination and proteasome-mediated degradation of TET2, thereby reducing PTEN expression and activating AKT to promote hepatocellular carcinoma proliferation. Wild-type FGFR3 does not interact with TET2.","method":"Mass spectrometry, co-immunoprecipitation, in vitro phosphorylation assay (Y1902 site), phospho-deficient mutant (Y1902F), ubiquitination assay, in vitro and xenograft in vivo proliferation assays","journal":"Cell death & disease","confidence":"High","confidence_rationale":"Tier 1 / Strong — mass spectrometry identification, co-IP validation, direct phosphorylation site mapping with mutagenesis (Y1902F), ubiquitination assay, in vivo rescue, multiple orthogonal methods","pmids":["33097695"],"is_preprint":false},{"year":2020,"finding":"fgfr3 loss-of-function in zebrafish causes delay in osteoblast expansion and differentiation during skull vault development, together with changes in extracellular matrix, establishing FGFR3 as a positive regulator of osteogenesis in cranial membranous bone formation.","method":"Fgfr3 loss-of-function zebrafish (fgfr3lof/lof), in vivo imaging, single-cell RNA sequencing of osteoblast lineage","journal":"Journal of bone and mineral research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic loss-of-function with in vivo imaging and single-cell transcriptomics, ortholog in zebrafish, single lab","pmids":["32379366"],"is_preprint":false},{"year":2020,"finding":"FGFR3 overexpression in DDP-resistant ovarian cancer cells enhances cisplatin resistance by phosphorylating EGFR and thereby activating the PI3K/AKT pathway; FGFR3 silencing suppresses EGFR phosphorylation and PI3K/AKT activation and restores DDP sensitivity in vitro and in nude mouse xenografts.","method":"Co-expression analysis, siRNA knockdown, FGFR3 overexpression, Western blot for EGFR phosphorylation and PI3K/AKT, cell viability assays, nude mouse xenograft","journal":"Biochemical pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain-of-function and loss-of-function with downstream signaling readouts and in vivo validation, single lab","pmids":["33794187"],"is_preprint":false},{"year":2020,"finding":"FGFR3 in periosteal cells (PCs) is required for terminal chondrocyte hypertrophy and cartilage-to-bone transformation during fracture healing; Fgfr3Y637C/+ PCs fail to undergo this transformation and cause pseudarthrosis/fibrocartilage, while transplantation of wild-type PCs rescues this defect.","method":"Conditional knock-in Fgfr3Y637C/+ (Prx1Cre), fracture model, periosteal cell transplantation, histological and lineage analysis","journal":"Stem cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional genetic model plus cell transplantation rescue experiment, single lab, clear phenotypic readout","pmids":["32916123"],"is_preprint":false}],"current_model":"FGFR3 is a receptor tyrosine kinase that signals through dimerization (stabilized by its transmembrane and juxtamembrane domains) and activation-loop tyrosine phosphorylation, activating downstream cascades including MAPK/ERK, STAT1/STAT3, PI3K/AKT, and PLC-γ; in cartilage it acts as a negative regulator of chondrocyte proliferation and differentiation by suppressing IHH and BMP signaling (promoting BMPR1a degradation via Smurf1-mediated ubiquitination), while in cancer settings gain-of-function mutations or oncogenic FGFR3-TACC3 fusions drive constitutive kinase activity, alternative metabolic reprogramming through the PIN4-peroxisome-ROS-PGC1α axis, and EGFR transphosphorylation, and FGFR3 is internalized via both clathrin-dependent and clathrin-independent mechanisms that modulate signaling duration."},"narrative":{"mechanistic_narrative":"FGFR3 is a receptor tyrosine kinase that signals through ligand-induced or constitutive dimerization and activation-loop tyrosine phosphorylation to engage MAPK/ERK, STAT1/STAT3, PI3K, PLC-γ and Shp2 effectors [PMID:10918587, PMID:19901323]. Dimerization is stabilized by intracellular receptor-receptor contacts: the juxtamembrane domain stabilizes unliganded dimers when linked to the transmembrane segment, and transmembrane-domain mutations such as G375C/G380R promote ligand-independent dimerization and phosphorylation [PMID:10587515, PMID:21324899, PMID:25688803]. In the developing skeleton FGFR3 acts as a negative regulator of chondrocyte proliferation and differentiation, signaling through ERK to suppress Indian hedgehog—its loss elevating IHH and producing chondroma-like lesions [PMID:10646125, PMID:26091072]—and inhibiting BMP signaling by driving Smurf1-mediated ubiquitination and degradation of the BMP type I receptor BMPR1a, a function independent of FGFR3 kinase activity [PMID:24657641]. FGFR3 signaling also coordinates membranous ossification, synchondrosis closure, and the cartilage-to-bone transition during growth and fracture repair, acting in part through paracrine effects of mutant chondrocytes on osteoblasts and osteoclasts [PMID:18923003, PMID:22367969, PMID:32916123]. Gain-of-function FGFR3 mutations cause achondroplasia and thanatophoric dysplasia, and extracellular-domain-targeting peptide inhibitors and statins reverse these skeletal phenotypes in disease models [PMID:10587515, PMID:23014564, PMID:25231866]. In cancer, activating FGFR3 mutations substitute for Ras to drive MAPK signaling in urothelial carcinoma [PMID:15897885], oncogenic FGFR3-TACC3 fusions confer constitutive kinase activity and metabolic reprogramming through a PIN4–peroxisome–ROS–PGC1α axis [PMID:26869289, PMID:29323298], and FGFR3 transphosphorylates EGFR to sustain PI3K/AKT signaling [PMID:33794187]. FGFR3 is internalized by both clathrin-dependent and clathrin-independent routes, modulating signaling duration [PMID:21779335].","teleology":[{"year":1995,"claim":"Established that FGFR3 mutations are pleiotropic—affecting skin as well as the skeleton—when a transmembrane-domain substitution was found in Crouzon syndrome with acanthosis nigricans, broadening the disease scope of FGFR3 beyond dwarfism.","evidence":"Mutation analysis / DNA sequencing in unrelated patient families","pmids":["7493034"],"confidence":"Medium","gaps":["No functional reconstitution of the Ala391Glu allele","Mechanism linking the receptor mutation to the skin phenotype unresolved"]},{"year":1999,"claim":"Resolved how a transmembrane-domain mutation activates FGFR3 by showing G375C/G369C causes ligand-independent dimerization and phosphorylation, linking constitutive receptor activity to growth-plate disorganization and dwarfism in vivo.","evidence":"Biochemical dimerization/phosphorylation assays plus knock-in mouse with growth-plate histology","pmids":["10587515"],"confidence":"High","gaps":["Did not map the full downstream effector cascade","Stat activation correlative within the model"]},{"year":2000,"claim":"Defined the downstream signaling repertoire of activated FGFR3 by showing a constitutively active kinase-domain mutant engages Shp2, PLC-γ, MAPK, Stat1/Stat3 and PI3K and transforms cells, establishing the effector network.","evidence":"In vitro signaling assays, NIH3T3 transformation, PC12 neurite outgrowth with K650E mutant","pmids":["10918587"],"confidence":"High","gaps":["Effectors defined with a single hyperactive mutant","Quantitative contribution of each pathway not dissected"]},{"year":2000,"claim":"Provided a cellular mechanism for FGFR3-mediated inhibition of chondrocytes, showing the active receptor blocks proliferation and differentiation and alters integrin-dependent matrix preference.","evidence":"Stable expression of FGFR3Ach (G380R) in chondrocytic cells with proliferation, differentiation and apoptosis assays","pmids":["10646125"],"confidence":"Medium","gaps":["Single cell line and lab","Did not identify the transcriptional mediators of growth arrest"]},{"year":2003,"claim":"Identified a CNS role for FGFR3 as a marker and repressor of astrocyte GFAP expression, extending its biology beyond cartilage.","evidence":"Fgfr3-null mouse with GFAP immunostaining of grey-matter astrocytes","pmids":["12441294"],"confidence":"Medium","gaps":["Downstream pathway controlling GFAP repression unknown","Ligand driving astrocytic signaling not identified"]},{"year":2005,"claim":"Placed FGFR3 firmly upstream of MAPK in tumorigenesis by demonstrating mutual exclusivity of FGFR3 and Ras mutations in urothelial carcinoma, implying both activate the same oncogenic pathway.","evidence":"Mutation screening of bladder tumours and cell lines with statistical epistasis analysis","pmids":["15897885"],"confidence":"Medium","gaps":["Correlative genetic epistasis, not functional","Did not establish dependency of tumours on the pathway"]},{"year":2007,"claim":"Revealed compartment-specific activation, showing intracellular-domain mutants are prematurely phosphorylated in the Golgi and impair receptor glycosylation, linking mutation class to subcellular signaling site.","evidence":"Transfection of FGFR3 mutant panel with phosphorylation/glycosylation Western blots","pmids":["17320202"],"confidence":"Medium","gaps":["Functional consequence of Golgi signaling for disease not established","Single-lab cell-culture observation"]},{"year":2009,"claim":"Systematically mapped the FGFR3 phosphotyrosine network in a disease cell context, identifying activation-loop tyrosines and 52 inhibitor-sensitive substrates including Syndecan-1.","evidence":"Label-free quantitative phosphoproteomics with FGFR3 inhibitor PD173074 in multiple myeloma cells","pmids":["19901323"],"confidence":"High","gaps":["Direct vs indirect substrates not all distinguished","Functional role of individual network nodes untested"]},{"year":2011,"claim":"Distinguished FGFR3 trafficking from FGFR1 by showing FGFR3 uses both clathrin-dependent and clathrin/dynamin-independent endocytosis, with internalization route shaping degradation and signaling duration.","evidence":"Clathrin depletion, dominant-negative dynamin, live imaging and signaling assays versus FGFR1","pmids":["21779335"],"confidence":"High","gaps":["Molecular machinery of the clathrin-independent route not defined","Link between trafficking and disease signaling unexplored"]},{"year":2011,"claim":"Quantified the biophysical basis of the achondroplasia mutation, showing G380R alters heterodimerization probability with wild-type receptor at low ligand.","evidence":"Cell-based dimerization assay using a truncated kinase-dead FGFR3 construct","pmids":["21324899"],"confidence":"Medium","gaps":["Indirect measure via dominant-negative depletion","Single lab"]},{"year":2008,"claim":"Defined the skeletal output and physiological limits of FGFR3: it promotes synchondrosis closure and BMP-dependent ossification, but is not the principal renal mediator of FGF23 signaling, narrowing its endocrine role.","evidence":"Chondrocyte-specific Fgfr3 activation mice and Fgfr3/Fgfr4-null × Hyp crosses with histology and physiological readouts","pmids":["18923003","18753255"],"confidence":"High","gaps":["Direct BMP target genes not all defined","Redundancy among FGFRs in other tissues not fully mapped"]},{"year":2012,"claim":"Dissected the cellular geography of skeletal disease by showing FGFR3 gain-of-function impairs both endochondral and membranous bone and acts on bone via a paracrine signal from cartilage rather than direct osteoblast effects.","evidence":"Ubiquitous, chondrocyte-specific and osteoblast-specific Fgfr3(Y367C) knock-in mice with histomorphometry","pmids":["24419316","22367969"],"confidence":"High","gaps":["Identity of the paracrine signal to osteoblasts/osteoclasts not defined","Mechanism of membranous defect unresolved"]},{"year":2013,"claim":"Defined a bona fide oncogenic FGFR3 species by showing the FGFR3-TACC3 fusion, but not wild-type overexpression, is tumorigenic and escapes miR-99a regulation.","evidence":"Whole transcriptome sequencing, proliferation assays, xenografts and miRNA binding analysis in glioblastoma","pmids":["23298836"],"confidence":"High","gaps":["Mechanism of constitutive activation not yet resolved in this study","Downstream signaling of fusion not characterized here"]},{"year":2014,"claim":"Established a kinase-independent FGFR3 function and a developmental regulatory node by showing FGFR3 drives Smurf1-mediated BMPR1a degradation to inhibit BMP signaling and chondrogenesis, with Bmpr1a deletion rescuing Fgfr3-null overgrowth.","evidence":"Genetic epistasis rescue, ubiquitination and Smad phosphorylation assays","pmids":["24657641"],"confidence":"High","gaps":["How FGFR3 recruits Smurf1 to BMPR1a not mechanistically resolved","Relative weight of kinase-dependent vs -independent outputs in vivo unclear"]},{"year":2014,"claim":"Demonstrated druggability of FGFR3 in skeletal disease via an extracellular-domain-binding peptide that inhibits kinase activity, promotes chondrogenesis and rescues TDII mice.","evidence":"Phage display, in vitro kinase inhibition, differentiation assay and in vivo TDII rescue","pmids":["23014564"],"confidence":"High","gaps":["Peptide pharmacology and selectivity not fully characterized","Translational development beyond model not addressed"]},{"year":2014,"claim":"Identified a pharmacological corrective strategy by showing statins rescue cartilage and bone-growth phenotypes in patient iPSC chondrocytes and ACH mice.","evidence":"Patient iPSC-derived chondrocyte models and ACH mouse statin treatment","pmids":["25231866"],"confidence":"High","gaps":["Molecular target linking statins to FGFR3 signaling not defined","Long-term in vivo efficacy not assessed"]},{"year":2015,"claim":"Resolved the dimer-stabilizing role of the juxtamembrane domain, showing it stabilizes unliganded FGFR3 dimers additively with a pathogenic TM mutation when tethered to the TM segment.","evidence":"Quantitative FRET dimerization assays with deletion/chimeric constructs","pmids":["25688803"],"confidence":"Medium","gaps":["Structural detail of JM-mediated contacts not defined","Single biophysical lab"]},{"year":2015,"claim":"Placed FGFR3 upstream of an ERK→IHH axis in cartilage homeostasis by showing Fgfr3 loss reduces ERK, derepresses IHH and causes chondromas, reversible by IHH or MEK inhibition.","evidence":"Postnatal chondrocyte-specific Fgfr3 deletion with ERK assays and pharmacological epistasis","pmids":["26091072"],"confidence":"High","gaps":["Direct transcriptional link between ERK and IHH not defined","Relationship to BMPR1a pathway not integrated"]},{"year":2016,"claim":"Explained how the FGFR3-TACC3 fusion is constitutively active, showing the TACC3 coiled-coil drives FGFR3 autophosphorylation and MAPK activation while FGFR3 kinase activity is essential for transformation and TACC3 drives nuclear localization.","evidence":"TiO2-LC-MS/MS phosphoproteomics, kinase-dead and domain-deletion mutants, transformation and localization assays","pmids":["26869289"],"confidence":"High","gaps":["Nuclear function of the fusion not defined","In vivo relevance of nuclear localization untested"]},{"year":2018,"claim":"Uncovered a metabolic mechanism of FGFR3-TACC3 oncogenesis, showing the fusion phosphorylates PIN4 to trigger peroxisome biogenesis and ROS that converge on PGC1α to drive mitochondrial respiration and tumor growth.","evidence":"Transcriptional clustering, metabolic and ROS assays, phosphoproteomics and PGC1α activity assays in tumors and cell lines","pmids":["29323298"],"confidence":"High","gaps":["Generalizability beyond fusion-positive tumours unclear","Direct PIN4-to-peroxisome signaling steps incomplete"]},{"year":2018,"claim":"Linked FGFR3 mutation to tumour-promoting immune modulation, showing FGFR3 S249C suppresses early neutrophil influx during bladder carcinogenesis, with neutrophil depletion phenocopying the effect.","evidence":"FGFR3-mutant urothelium mice with carcinogen exposure and antibody-mediated neutrophil depletion","pmids":["30043421"],"confidence":"Medium","gaps":["Molecular mediator of neutrophil suppression unknown","Single carcinogen model"]},{"year":2019,"claim":"Connected FGFR3 to contact-inhibition loss by defining an ERK→ETV5→TAZ axis driving proliferation in mutant bladder cancer.","evidence":"FGFR3 inhibition/activation and ETV5 knockdown with proliferation and anchorage-independent growth assays","pmids":["30952872"],"confidence":"Medium","gaps":["Direct binding of ETV5 to TAZ regulatory elements not shown","In vivo validation absent"]},{"year":2019,"claim":"Extended FGFR3 function to lymphatic biology, showing FGFR3 promotes lymphatic endothelial cell formation via BMPR1a–pSmad1/5 signaling, with loss exacerbating inflammation and heterotopic ossification.","evidence":"Conditional Fgfr3 knockout, lineage tracing and FGF9 rescue in a heterotopic ossification model","pmids":["34282140"],"confidence":"Medium","gaps":["Cell-type-specific BMPR1a regulation versus chondrocyte degradation paradigm not reconciled","Single lab"]},{"year":2020,"claim":"Identified an isoform-specific oncogenic mechanism, showing the FGFR3Δ7-9 splice variant phosphorylates TET2 at Y1902 to trigger its degradation, lowering PTEN and activating AKT in hepatocellular carcinoma, whereas wild-type FGFR3 does not bind TET2.","evidence":"Mass spectrometry, co-IP, phosphosite mapping (Y1902F), ubiquitination assay and xenografts","pmids":["33097695"],"confidence":"High","gaps":["Prevalence of this splice variant across tumours unclear","Structural basis of variant-specific TET2 binding undefined"]},{"year":2020,"claim":"Established FGFR3 as a positive regulator of cranial osteogenesis, showing zebrafish fgfr3 loss delays osteoblast expansion and alters matrix during skull-vault formation, complementing mammalian membranous-bone phenotypes.","evidence":"fgfr3 loss-of-function zebrafish with in vivo imaging and single-cell RNA-seq","pmids":["32379366"],"confidence":"Medium","gaps":["Signaling pathway underlying osteoblast delay not defined","Conservation of mechanism to mammals not directly tested"]},{"year":2020,"claim":"Defined a periosteal requirement for FGFR3 in fracture repair, showing mutant periosteal cells fail terminal chondrocyte hypertrophy and cartilage-to-bone transformation, rescuable by wild-type cell transplantation.","evidence":"Conditional Fgfr3Y637C knock-in fracture model with periosteal cell transplantation","pmids":["32916123"],"confidence":"Medium","gaps":["Molecular block to hypertrophic transition not defined","Single lab"]},{"year":2020,"claim":"Revealed FGFR3 as a driver of therapy resistance via receptor cross-talk, showing FGFR3 transphosphorylates EGFR to activate PI3K/AKT and confer cisplatin resistance in ovarian cancer.","evidence":"FGFR3 overexpression/silencing with EGFR phosphorylation and PI3K/AKT readouts and xenografts","pmids":["33794187"],"confidence":"Medium","gaps":["Direct vs indirect EGFR transphosphorylation not resolved","Single lab"]},{"year":null,"claim":"How FGFR3's kinase-dependent (MAPK/ERK, STAT, PI3K) and kinase-independent (Smurf1-BMPR1a) outputs are integrated to set the balance between chondrocyte suppression, osteogenic promotion, and oncogenic signaling across tissues remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking endocytic route, signaling duration and pathway choice","Mechanism of context-dependent positive vs negative skeletal effects unexplained","Recruitment logic of Smurf1 and substrate selection by mutant/fusion forms undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[2,9,20,25,27]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[1,2,9,25]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[1,2,11,18]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[23]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[10,11,18]},{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[6]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[20]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[2,9,23,27]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[7,13,16,19,26,28]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[5,15,20,21,25]},{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[10]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[21]}],"complexes":[],"partners":["BMPR1A","SMURF1","TACC3","PIN4","TET2","EGFR","SDC1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P22607","full_name":"Fibroblast growth factor receptor 3","aliases":[],"length_aa":806,"mass_kda":87.7,"function":"Tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation and apoptosis. Plays an essential role in the regulation of chondrocyte differentiation, proliferation and apoptosis, and is required for normal skeleton development. Regulates both osteogenesis and postnatal bone mineralization by osteoblasts. Promotes apoptosis in chondrocytes, but can also promote cancer cell proliferation. Required for normal development of the inner ear. Phosphorylates PLCG1, CBL and FRS2. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Plays a role in the regulation of vitamin D metabolism. Mutations that lead to constitutive kinase activation or impair normal FGFR3 maturation, internalization and degradation lead to aberrant signaling. Over-expressed or constitutively activated FGFR3 promotes activation of PTPN11/SHP2, STAT1, STAT5A and STAT5B. Secreted isoform 3 retains its capacity to bind FGF1 and FGF2 and hence may interfere with FGF signaling","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/P22607/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/FGFR3","classification":"Not Classified","n_dependent_lines":7,"n_total_lines":1208,"dependency_fraction":0.005794701986754967},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/FGFR3","total_profiled":1310},"omim":[{"mim_id":"621149","title":"CHROMOSOME 6 OPEN READING FRAME 58; C6ORF58","url":"https://www.omim.org/entry/621149"},{"mim_id":"620192","title":"LACRIMOAURICULODENTODIGITAL SYNDROME 2; LADD2","url":"https://www.omim.org/entry/620192"},{"mim_id":"618736","title":"STRUCTURAL BRAIN ANOMALIES WITH IMPAIRED INTELLECTUAL DEVELOPMENT AND CRANIOSYNOSTOSIS; BAIDCS","url":"https://www.omim.org/entry/618736"},{"mim_id":"617425","title":"IMMUNOSKELETAL DYSPLASIA WITH NEURODEVELOPMENTAL ABNORMALITIES; ISDNA","url":"https://www.omim.org/entry/617425"},{"mim_id":"616482","title":"ACHONDROPLASIA, SEVERE, WITH DEVELOPMENTAL DELAY AND ACANTHOSIS NIGRICANS; SADDAN","url":"https://www.omim.org/entry/616482"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Endoplasmic reticulum","reliability":"Supported"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"brain","ntpm":148.8},{"tissue":"esophagus","ntpm":126.6},{"tissue":"skin 1","ntpm":256.5}],"url":"https://www.proteinatlas.org/search/FGFR3"},"hgnc":{"alias_symbol":["CEK2","JTK4","CD333"],"prev_symbol":["ACH"]},"alphafold":{"accession":"P22607","domains":[{"cath_id":"2.60.40.10","chopping":"47-127","consensus_level":"high","plddt":83.8357,"start":47,"end":127},{"cath_id":"2.60.40.10","chopping":"153-247","consensus_level":"medium","plddt":84.4121,"start":153,"end":247},{"cath_id":"2.60.40.10","chopping":"255-358","consensus_level":"medium","plddt":87.0966,"start":255,"end":358},{"cath_id":"3.30.200.20","chopping":"470-557","consensus_level":"high","plddt":88.3238,"start":470,"end":557},{"cath_id":"1.10.510.10","chopping":"562-575_587-759","consensus_level":"high","plddt":86.7888,"start":562,"end":759}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P22607","model_url":"https://alphafold.ebi.ac.uk/files/AF-P22607-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P22607-F1-predicted_aligned_error_v6.png","plddt_mean":74.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=FGFR3","jax_strain_url":"https://www.jax.org/strain/search?query=FGFR3"},"sequence":{"accession":"P22607","fasta_url":"https://rest.uniprot.org/uniprotkb/P22607.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P22607/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P22607"}},"corpus_meta":[{"pmid":"25639674","id":"PMC_25639674","title":"Nicotinic ACh receptors as therapeutic targets in CNS disorders.","date":"2015","source":"Trends in pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/25639674","citation_count":366,"is_preprint":false},{"pmid":"7493034","id":"PMC_7493034","title":"Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in Crouzon syndrome with acanthosis nigricans.","date":"1995","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/7493034","citation_count":325,"is_preprint":false},{"pmid":"23175443","id":"PMC_23175443","title":"Oncogenic FGFR3 gene fusions in bladder cancer.","date":"2012","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23175443","citation_count":319,"is_preprint":false},{"pmid":"15897885","id":"PMC_15897885","title":"FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma.","date":"2005","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/15897885","citation_count":256,"is_preprint":false},{"pmid":"10918587","id":"PMC_10918587","title":"Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4.","date":"2000","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/10918587","citation_count":222,"is_preprint":false},{"pmid":"10587515","id":"PMC_10587515","title":"Gly369Cys mutation in mouse FGFR3 causes achondroplasia by affecting both chondrogenesis and osteogenesis.","date":"1999","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/10587515","citation_count":206,"is_preprint":false},{"pmid":"23298836","id":"PMC_23298836","title":"The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma.","date":"2013","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/23298836","citation_count":192,"is_preprint":false},{"pmid":"15748888","id":"PMC_15748888","title":"Cell responses to FGFR3 signalling: growth, differentiation and apoptosis.","date":"2004","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/15748888","citation_count":180,"is_preprint":false},{"pmid":"29323298","id":"PMC_29323298","title":"A metabolic function of FGFR3-TACC3 gene fusions in cancer.","date":"2018","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/29323298","citation_count":161,"is_preprint":false},{"pmid":"25231866","id":"PMC_25231866","title":"Statin treatment rescues FGFR3 skeletal dysplasia phenotypes.","date":"2014","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/25231866","citation_count":157,"is_preprint":false},{"pmid":"22045636","id":"PMC_22045636","title":"Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias.","date":"2011","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/22045636","citation_count":156,"is_preprint":false},{"pmid":"36898352","id":"PMC_36898352","title":"Role of FGFR3 in bladder cancer: Treatment landscape and future challenges.","date":"2023","source":"Cancer treatment reviews","url":"https://pubmed.ncbi.nlm.nih.gov/36898352","citation_count":151,"is_preprint":false},{"pmid":"7610492","id":"PMC_7610492","title":"Molecular biology of the vesicular ACh transporter.","date":"1995","source":"Trends in neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/7610492","citation_count":139,"is_preprint":false},{"pmid":"12441294","id":"PMC_12441294","title":"Fgfr3 expression by astrocytes and their precursors: evidence that astrocytes and oligodendrocytes originate in distinct neuroepithelial domains.","date":"2003","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/12441294","citation_count":135,"is_preprint":false},{"pmid":"12237885","id":"PMC_12237885","title":"Frequent FGFR3 mutations in urothelial papilloma.","date":"2002","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/12237885","citation_count":134,"is_preprint":false},{"pmid":"12388234","id":"PMC_12388234","title":"ACh and adenosine activate PI3-kinase in rabbit hearts through transactivation of receptor tyrosine kinases.","date":"2002","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/12388234","citation_count":119,"is_preprint":false},{"pmid":"27409839","id":"PMC_27409839","title":"FGFR3-TACC3 fusion in solid tumors: mini review.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27409839","citation_count":113,"is_preprint":false},{"pmid":"18753255","id":"PMC_18753255","title":"FGFR3 and FGFR4 do not mediate renal effects of FGF23.","date":"2008","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/18753255","citation_count":113,"is_preprint":false},{"pmid":"8589686","id":"PMC_8589686","title":"A common FGFR3 gene mutation in hypochondroplasia.","date":"1995","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8589686","citation_count":109,"is_preprint":false},{"pmid":"10585567","id":"PMC_10585567","title":"Expression of FGFR1, FGFR2 and FGFR3 during early neural development in the chick embryo.","date":"2000","source":"Mechanisms of development","url":"https://pubmed.ncbi.nlm.nih.gov/10585567","citation_count":108,"is_preprint":false},{"pmid":"18923003","id":"PMC_18923003","title":"FGFR3 promotes synchondrosis closure and fusion of ossification centers through the MAPK pathway.","date":"2008","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18923003","citation_count":107,"is_preprint":false},{"pmid":"17912529","id":"PMC_17912529","title":"Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target.","date":"2007","source":"World journal of urology","url":"https://pubmed.ncbi.nlm.nih.gov/17912529","citation_count":98,"is_preprint":false},{"pmid":"23830821","id":"PMC_23830821","title":"Biogenesis, trafficking and up-regulation of nicotinic ACh receptors.","date":"2013","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/23830821","citation_count":96,"is_preprint":false},{"pmid":"11314002","id":"PMC_11314002","title":"Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma.","date":"2001","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11314002","citation_count":89,"is_preprint":false},{"pmid":"27022737","id":"PMC_27022737","title":"Long noncoding RNA FGFR3-AS1 promotes osteosarcoma growth through regulating its natural antisense transcript FGFR3.","date":"2016","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/27022737","citation_count":85,"is_preprint":false},{"pmid":"25809917","id":"PMC_25809917","title":"Mutations in TERT promoter and FGFR3 and telomere length in bladder cancer.","date":"2015","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25809917","citation_count":82,"is_preprint":false},{"pmid":"22099989","id":"PMC_22099989","title":"The FGFR3 mutation is related to favorable pT1 bladder cancer.","date":"2011","source":"The Journal of urology","url":"https://pubmed.ncbi.nlm.nih.gov/22099989","citation_count":82,"is_preprint":false},{"pmid":"25535896","id":"PMC_25535896","title":"Recurrent FGFR3-TACC3 fusion gene in nasopharyngeal carcinoma.","date":"2014","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/25535896","citation_count":75,"is_preprint":false},{"pmid":"25595880","id":"PMC_25595880","title":"The integrated role of ACh, ERK and mTOR in the mechanisms of hippocampal inhibitory avoidance memory.","date":"2015","source":"Neurobiology of learning and memory","url":"https://pubmed.ncbi.nlm.nih.gov/25595880","citation_count":75,"is_preprint":false},{"pmid":"26869289","id":"PMC_26869289","title":"Oncogenic Gene Fusion FGFR3-TACC3 Is Regulated by Tyrosine Phosphorylation.","date":"2016","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/26869289","citation_count":74,"is_preprint":false},{"pmid":"21139072","id":"PMC_21139072","title":"Compound deletion of Fgfr3 and Fgfr4 partially rescues the Hyp mouse phenotype.","date":"2010","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/21139072","citation_count":73,"is_preprint":false},{"pmid":"32682615","id":"PMC_32682615","title":"FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?†.","date":"2020","source":"European urology","url":"https://pubmed.ncbi.nlm.nih.gov/32682615","citation_count":72,"is_preprint":false},{"pmid":"21792889","id":"PMC_21792889","title":"Mechanisms of FGFR3 actions in endocrine resistant breast cancer.","date":"2011","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21792889","citation_count":72,"is_preprint":false},{"pmid":"21547910","id":"PMC_21547910","title":"Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma.","date":"2011","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/21547910","citation_count":70,"is_preprint":false},{"pmid":"28043938","id":"PMC_28043938","title":"mTORC1 activation downregulates FGFR3 and PTH/PTHrP receptor in articular chondrocytes to initiate osteoarthritis.","date":"2016","source":"Osteoarthritis and cartilage","url":"https://pubmed.ncbi.nlm.nih.gov/28043938","citation_count":69,"is_preprint":false},{"pmid":"24419316","id":"PMC_24419316","title":"FGFR3 mutation causes abnormal membranous ossification in achondroplasia.","date":"2014","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24419316","citation_count":62,"is_preprint":false},{"pmid":"31987043","id":"PMC_31987043","title":"FGFR3 signaling and function in triple negative breast cancer.","date":"2020","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/31987043","citation_count":61,"is_preprint":false},{"pmid":"15869706","id":"PMC_15869706","title":"Clinical and biological characteristics of cervical neoplasias with FGFR3 mutation.","date":"2005","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/15869706","citation_count":60,"is_preprint":false},{"pmid":"33224141","id":"PMC_33224141","title":"FGFR3 Alterations in the Era of Immunotherapy for Urothelial Bladder Cancer.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33224141","citation_count":56,"is_preprint":false},{"pmid":"32413119","id":"PMC_32413119","title":"Clinical, molecular, and radiomic profile of gliomas with FGFR3-TACC3 fusions.","date":"2020","source":"Neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32413119","citation_count":56,"is_preprint":false},{"pmid":"31690697","id":"PMC_31690697","title":"Clinical characterisation of sensory neuropathy with anti-FGFR3 autoantibodies.","date":"2019","source":"Journal of neurology, neurosurgery, and psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/31690697","citation_count":55,"is_preprint":false},{"pmid":"28976058","id":"PMC_28976058","title":"Diffuse gliomas with FGFR3-TACC3 fusion have characteristic histopathological and molecular features.","date":"2017","source":"Brain pathology (Zurich, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/28976058","citation_count":54,"is_preprint":false},{"pmid":"10646125","id":"PMC_10646125","title":"Expression of FGFR3 with the G380R achondroplasia mutation inhibits proliferation and maturation of CFK2 chondrocytic cells.","date":"2000","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/10646125","citation_count":53,"is_preprint":false},{"pmid":"11287195","id":"PMC_11287195","title":"fgfr3 and regionalization of anterior neural tube in zebrafish.","date":"2001","source":"Mechanisms of development","url":"https://pubmed.ncbi.nlm.nih.gov/11287195","citation_count":48,"is_preprint":false},{"pmid":"34202925","id":"PMC_34202925","title":"Regulation of Immune Functions by Non-Neuronal Acetylcholine (ACh) via Muscarinic and Nicotinic ACh Receptors.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34202925","citation_count":47,"is_preprint":false},{"pmid":"32038996","id":"PMC_32038996","title":"MicroRNA-99a Suppresses Breast Cancer Progression by Targeting FGFR3.","date":"2020","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32038996","citation_count":47,"is_preprint":false},{"pmid":"31619201","id":"PMC_31619201","title":"FGFR3 promotes the growth and malignancy of melanoma by influencing EMT and the phosphorylation of ERK, AKT, and EGFR.","date":"2019","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/31619201","citation_count":47,"is_preprint":false},{"pmid":"20539070","id":"PMC_20539070","title":"Overexpression of KLF13 and FGFR3 in oral cancer cells.","date":"2010","source":"Cytogenetic and genome research","url":"https://pubmed.ncbi.nlm.nih.gov/20539070","citation_count":46,"is_preprint":false},{"pmid":"26091072","id":"PMC_26091072","title":"FGFR3 Deficiency Causes Multiple Chondroma-like Lesions by Upregulating Hedgehog Signaling.","date":"2015","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26091072","citation_count":46,"is_preprint":false},{"pmid":"7702086","id":"PMC_7702086","title":"A common FGFR3 gene mutation is present in achondroplasia but not in hypochondroplasia.","date":"1995","source":"American journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/7702086","citation_count":43,"is_preprint":false},{"pmid":"19901323","id":"PMC_19901323","title":"Multiple myeloma phosphotyrosine proteomic profile associated with FGFR3 expression, ligand activation, and drug inhibition.","date":"2009","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/19901323","citation_count":41,"is_preprint":false},{"pmid":"21779335","id":"PMC_21779335","title":"Clathrin- and dynamin-independent endocytosis of FGFR3--implications for signalling.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21779335","citation_count":40,"is_preprint":false},{"pmid":"32060985","id":"PMC_32060985","title":"LncRNA KCNQ1OT1 accelerates fracture healing via modulating miR-701-3p/FGFR3 axis.","date":"2020","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/32060985","citation_count":40,"is_preprint":false},{"pmid":"23014564","id":"PMC_23014564","title":"A novel FGFR3-binding peptide inhibits FGFR3 signaling and reverses the lethal phenotype of mice mimicking human thanatophoric dysplasia.","date":"2012","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23014564","citation_count":40,"is_preprint":false},{"pmid":"32916123","id":"PMC_32916123","title":"FGFR3 in Periosteal Cells Drives Cartilage-to-Bone Transformation in Bone Repair.","date":"2020","source":"Stem cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/32916123","citation_count":39,"is_preprint":false},{"pmid":"24657641","id":"PMC_24657641","title":"FGFR3 induces degradation of BMP type I receptor to regulate skeletal development.","date":"2014","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/24657641","citation_count":39,"is_preprint":false},{"pmid":"20582225","id":"PMC_20582225","title":"Generation of Fgfr3 conditional knockout mice.","date":"2010","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/20582225","citation_count":39,"is_preprint":false},{"pmid":"22367969","id":"PMC_22367969","title":"An activating Fgfr3 mutation affects trabecular bone formation via a paracrine mechanism during growth.","date":"2012","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22367969","citation_count":39,"is_preprint":false},{"pmid":"23902722","id":"PMC_23902722","title":"FGFR3 has tumor suppressor properties in cells with epithelial phenotype.","date":"2013","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/23902722","citation_count":37,"is_preprint":false},{"pmid":"33792960","id":"PMC_33792960","title":"TS-HDS and FGFR3 antibodies in small fiber neuropathy and Dysautonomia.","date":"2021","source":"Muscle & nerve","url":"https://pubmed.ncbi.nlm.nih.gov/33792960","citation_count":35,"is_preprint":false},{"pmid":"25777271","id":"PMC_25777271","title":"A novel variant of FGFR3 causes proportionate short stature.","date":"2015","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/25777271","citation_count":35,"is_preprint":false},{"pmid":"27998968","id":"PMC_27998968","title":"Drug-sensitive FGFR3 mutations in lung adenocarcinoma.","date":"2017","source":"Annals of oncology : official journal of the European Society for Medical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/27998968","citation_count":34,"is_preprint":false},{"pmid":"25688803","id":"PMC_25688803","title":"FGFR3 unliganded dimer stabilization by the juxtamembrane domain.","date":"2015","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/25688803","citation_count":34,"is_preprint":false},{"pmid":"21324899","id":"PMC_21324899","title":"FGFR3 heterodimerization in achondroplasia, the most common form of human dwarfism.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21324899","citation_count":34,"is_preprint":false},{"pmid":"19287463","id":"PMC_19287463","title":"FGFR3 and TP53 mutation analysis in inverted urothelial papilloma: incidence and etiological considerations.","date":"2009","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/19287463","citation_count":33,"is_preprint":false},{"pmid":"19422094","id":"PMC_19422094","title":"FGFR3-targeted mAb therapy for bladder cancer and multiple myeloma.","date":"2009","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/19422094","citation_count":32,"is_preprint":false},{"pmid":"22559284","id":"PMC_22559284","title":"FGFR3 targeting strategies for achondroplasia.","date":"2012","source":"Expert reviews in molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22559284","citation_count":31,"is_preprint":false},{"pmid":"33794187","id":"PMC_33794187","title":"FGFR3 phosphorylates EGFR to promote cisplatin-resistance in ovarian cancer.","date":"2021","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33794187","citation_count":31,"is_preprint":false},{"pmid":"28379477","id":"PMC_28379477","title":"Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomas.","date":"2017","source":"Neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/28379477","citation_count":31,"is_preprint":false},{"pmid":"30685387","id":"PMC_30685387","title":"Suppressing UPR-dependent overactivation of FGFR3 signaling ameliorates SLC26A2-deficient chondrodysplasias.","date":"2019","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/30685387","citation_count":31,"is_preprint":false},{"pmid":"34282140","id":"PMC_34282140","title":"Targeting local lymphatics to ameliorate heterotopic ossification via FGFR3-BMPR1a pathway.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34282140","citation_count":29,"is_preprint":false},{"pmid":"15936779","id":"PMC_15936779","title":"Expression of acetylcholine (ACh) and ACh-synthesizing activity in Archaea.","date":"2005","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/15936779","citation_count":29,"is_preprint":false},{"pmid":"30043421","id":"PMC_30043421","title":"FGFR3 mutation increases bladder tumourigenesis by suppressing acute inflammation.","date":"2018","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/30043421","citation_count":29,"is_preprint":false},{"pmid":"22188534","id":"PMC_22188534","title":"FGFR3, PIK3CA and RAS mutations in benign lichenoid keratosis.","date":"2012","source":"The British journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/22188534","citation_count":29,"is_preprint":false},{"pmid":"24880661","id":"PMC_24880661","title":"FGFR3 mutations, but not FGFR3 expression and FGFR3 copy-number variations, are associated with favourable non-muscle invasive bladder cancer.","date":"2014","source":"Virchows Archiv : an international journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/24880661","citation_count":27,"is_preprint":false},{"pmid":"20453470","id":"PMC_20453470","title":"FGFR3 mutations and the skin: report of a patient with a FGFR3 gene mutation, acanthosis nigricans, hypochondroplasia and hyperinsulinemia and review of the literature.","date":"2010","source":"Dermatology (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/20453470","citation_count":27,"is_preprint":false},{"pmid":"20420824","id":"PMC_20420824","title":"FGFR3 mutation affects cell growth, apoptosis and attachment in keratinocytes.","date":"2010","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/20420824","citation_count":26,"is_preprint":false},{"pmid":"19845664","id":"PMC_19845664","title":"FGFR3 and PIK3CA mutations in stucco keratosis and dermatosis papulosa nigra.","date":"2009","source":"The British journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/19845664","citation_count":26,"is_preprint":false},{"pmid":"9630614","id":"PMC_9630614","title":"Modulation of ACh receptor currents by arachidonic acid.","date":"1998","source":"Brain research. Molecular brain research","url":"https://pubmed.ncbi.nlm.nih.gov/9630614","citation_count":26,"is_preprint":false},{"pmid":"17320202","id":"PMC_17320202","title":"FGFR3 intracellular mutations induce tyrosine phosphorylation in the Golgi and defective glycosylation.","date":"2007","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/17320202","citation_count":26,"is_preprint":false},{"pmid":"26075305","id":"PMC_26075305","title":"FGFR3 biology and skeletal disease.","date":"2015","source":"Connective tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/26075305","citation_count":25,"is_preprint":false},{"pmid":"28779179","id":"PMC_28779179","title":"mTORC1 regulates apoptosis and cell proliferation in pterygium via targeting autophagy and FGFR3.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28779179","citation_count":24,"is_preprint":false},{"pmid":"36647073","id":"PMC_36647073","title":"Clinico-pathological and epigenetic heterogeneity of diffuse gliomas with FGFR3::TACC3 fusion.","date":"2023","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/36647073","citation_count":23,"is_preprint":false},{"pmid":"30952872","id":"PMC_30952872","title":"ETV5 links the FGFR3 and Hippo signalling pathways in bladder cancer.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/30952872","citation_count":23,"is_preprint":false},{"pmid":"26861974","id":"PMC_26861974","title":"FGFR3 and Cyclin D3 as urine biomarkers of bladder cancer recurrence.","date":"2016","source":"Biomarkers in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26861974","citation_count":23,"is_preprint":false},{"pmid":"32379366","id":"PMC_32379366","title":"Fgfr3 Is a Positive Regulator of Osteoblast Expansion and Differentiation During Zebrafish Skull Vault Development.","date":"2020","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/32379366","citation_count":23,"is_preprint":false},{"pmid":"8586414","id":"PMC_8586414","title":"Genomic organization of the mouse fibroblast growth factor receptor 3 (Fgfr3) gene.","date":"1995","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/8586414","citation_count":23,"is_preprint":false},{"pmid":"11406485","id":"PMC_11406485","title":"Role of nitric oxide and protein kinase C in ACh-induced cardioprotection.","date":"2001","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/11406485","citation_count":22,"is_preprint":false},{"pmid":"33097695","id":"PMC_33097695","title":"FGFR3△7-9 promotes tumor progression via the phosphorylation and destabilization of ten-eleven translocation-2 in human hepatocellular carcinoma.","date":"2020","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/33097695","citation_count":22,"is_preprint":false},{"pmid":"35955806","id":"PMC_35955806","title":"FGFR3-TACCs3 Fusions and Their Clinical Relevance in Human Glioblastoma.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35955806","citation_count":20,"is_preprint":false},{"pmid":"30124558","id":"PMC_30124558","title":"FGFR3 Antibodies in Neuropathy: What to Do With Them?","date":"2018","source":"Journal of clinical neuromuscular disease","url":"https://pubmed.ncbi.nlm.nih.gov/30124558","citation_count":20,"is_preprint":false},{"pmid":"30064409","id":"PMC_30064409","title":"Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma.","date":"2018","source":"BMC urology","url":"https://pubmed.ncbi.nlm.nih.gov/30064409","citation_count":20,"is_preprint":false},{"pmid":"21521775","id":"PMC_21521775","title":"FGFR3 is overexpressed waldenstrom macroglobulinemia and its inhibition by Dovitinib induces apoptosis and overcomes stroma-induced proliferation.","date":"2011","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/21521775","citation_count":20,"is_preprint":false},{"pmid":"34840077","id":"PMC_34840077","title":"Targeted therapies: Expanding the role of FGFR3 inhibition in urothelial carcinoma.","date":"2021","source":"Urologic oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34840077","citation_count":19,"is_preprint":false},{"pmid":"26254388","id":"PMC_26254388","title":"TP53 and FGFR3 Gene Mutation Assessment in Urine: Pilot Study for Bladder Cancer Diagnosis.","date":"2015","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/26254388","citation_count":18,"is_preprint":false},{"pmid":"35501832","id":"PMC_35501832","title":"Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer.","date":"2022","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/35501832","citation_count":18,"is_preprint":false},{"pmid":"26682470","id":"PMC_26682470","title":"Complementary roles of the Cek1 and Cek2 MAP kinases in Candida albicans cell-wall biogenesis.","date":"2015","source":"Future microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/26682470","citation_count":17,"is_preprint":false},{"pmid":"31528172","id":"PMC_31528172","title":"Role of FGFR3 in Urothelial Carcinoma.","date":"2019","source":"Iranian journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31528172","citation_count":17,"is_preprint":false},{"pmid":"37169979","id":"PMC_37169979","title":"Spectroscopic Determination of Acetylcholine (ACh): A Representative Review.","date":"2023","source":"Topics in current chemistry (Cham)","url":"https://pubmed.ncbi.nlm.nih.gov/37169979","citation_count":17,"is_preprint":false},{"pmid":"23649205","id":"PMC_23649205","title":"Temporal and occipital lobe features in children with hypochondroplasia/FGFR3 gene mutation.","date":"2013","source":"Pediatric radiology","url":"https://pubmed.ncbi.nlm.nih.gov/23649205","citation_count":17,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":51735,"output_tokens":7632,"usd":0.134843,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":16940,"output_tokens":7619,"usd":0.137588,"stage2_stop_reason":"end_turn"},"total_usd":0.272431,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1995,\n      \"finding\": \"A missense mutation Ala391Glu in the FGFR3 transmembrane domain was identified in Crouzon syndrome with acanthosis nigricans, demonstrating that transmembrane domain mutations in FGFR3 can cause non-skeletal (skin) disorders in addition to dwarfing conditions, and revealing pleiotropic effects of FGFR3 mutations.\",\n      \"method\": \"Mutation analysis / DNA sequencing in unrelated patient families\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — mutation identified in multiple unrelated families, single method (sequencing), no in vitro functional reconstitution\",\n      \"pmids\": [\"7493034\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"The G375C (human)/G369C (mouse) substitution in the FGFR3 transmembrane domain causes ligand-independent dimerization and phosphorylation of FGFR3 in cells, leading to achondroplasia-like dwarfism in mice with expanded resting zone, narrowed proliferating and hypertrophic zones in growth plates, activation of Stat proteins, upregulation of cell-cycle inhibitors, increased osteoclast activity, and upregulation of osteoblast differentiation genes.\",\n      \"method\": \"Biochemical assay (dimerization, phosphorylation), mouse genetic model (knock-in), histological and molecular analysis of growth plate\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — in vitro biochemical demonstration of ligand-independent dimerization and phosphorylation plus knock-in mouse model with multiple orthogonal readouts\",\n      \"pmids\": [\"10587515\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Constitutively active FGFR3 (K650E activation loop mutation, TDII-like) phosphorylates Shp2, PLC-gamma, and MAPK, activates Stat1 and Stat3, stimulates PI3-kinase activity, transforms NIH3T3 cells, and induces neurite outgrowth in PC12 cells, defining downstream effectors of FGFR3 kinase activation.\",\n      \"method\": \"In vitro kinase/signaling assays, NIH3T3 transformation assay, PC12 neurite outgrowth assay, Western blot for downstream effectors\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal signaling assays and functional transformation assays in one study with activated mutant\",\n      \"pmids\": [\"10918587\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Stable expression of constitutively active FGFR3Ach (G380R) in CFK2 chondrocytic cells severely inhibits proliferation and prevents differentiation, induces abnormal apoptosis upon serum deprivation, and alters integrin subunit expression leading to a switch in substrate preference from fibronectin to type II collagen, providing a cellular mechanism for FGFR3-mediated inhibition of chondrocyte proliferation.\",\n      \"method\": \"Stable transfection of chondrocytic cell line, proliferation assays, differentiation assays, apoptosis assays, integrin expression analysis\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — defined cellular phenotypes with multiple readouts in a single lab using constitutively active mutant\",\n      \"pmids\": [\"10646125\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Fgfr3 marks astrocytes and their neuroepithelial precursors in the developing CNS, and FGFR3 signaling normally represses GFAP expression in grey matter (protoplasmic) astrocytes, as demonstrated by strong upregulation of GFAP in grey matter astrocytes of Fgfr3-null mice.\",\n      \"method\": \"Fgfr3 knockout mouse analysis, in vitro and in vivo immunostaining, cell co-expression analysis\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic loss-of-function with specific molecular readout (GFAP upregulation), single lab\",\n      \"pmids\": [\"12441294\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"FGFR3 mutations and Ras gene mutations are mutually exclusive in urothelial cell carcinoma (UCC), indicating that FGFR3 activating mutations and Ras mutations represent alternative means to activate the MAPK pathway and confer the same oncogenic phenotype.\",\n      \"method\": \"Mutation screening of 98 bladder tumours and 31 cell lines for FGFR3, HRAS, NRAS, and KRAS2 mutations; statistical mutual exclusivity analysis\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — large sample genetic epistasis analysis demonstrating mutual exclusivity as pathway evidence, single method\",\n      \"pmids\": [\"15897885\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"FGFR3 intracellular domain mutations (but not extracellular or transmembrane domain mutations) induce premature tyrosine phosphorylation of the receptor in the Golgi apparatus and inhibit receptor glycosylation, suggesting that premature kinase activation prevents glycosylation and leads to elevated Golgi-associated signaling.\",\n      \"method\": \"HEK cell transfection with various FGFR3 mutants, Western blotting for phosphorylation and glycosylation state\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple FGFR3 mutants tested in cell culture with orthogonal readouts (phosphorylation and glycosylation), single lab\",\n      \"pmids\": [\"17320202\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"FGFR3 and MAPK signaling in chondrocytes promote synchondrosis closure and fusion of ossification centers; chondrocyte-specific activation of Fgfr3 in mice induced premature synchondrosis closure, enhanced osteoblast differentiation around synchondroses, increased Bmp ligand mRNA expression, and decreased Bmp antagonist mRNA expression in a MAPK-dependent manner.\",\n      \"method\": \"Mouse genetic models (chondrocyte-specific Fgfr3 activation), histology, gene expression analysis\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — tissue-specific genetic activation with multiple orthogonal readouts (histology, gene expression, BMP pathway changes), clear pathway placement\",\n      \"pmids\": [\"18923003\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"FGFR3 (and FGFR4) do not mediate the principal renal effects of FGF23: ablation of FGFR3 alone or together with FGFR4 failed to correct hypophosphatemia or restore 1,25(OH)2D in Hyp mice, while FGFR1 co-localizes with Klotho in distal tubule, suggesting FGFR1 as the primary mediator of FGF23 renal effects.\",\n      \"method\": \"Genetic knockout (Fgfr3-null, Fgfr4-null) crossed with Hyp mouse model, serum phosphate and 1,25(OH)2D measurements, immunohistochemistry\",\n      \"journal\": \"Journal of the American Society of Nephrology : JASN\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo genetic loss-of-function with physiological readouts, negative result for FGFR3 as FGF23 receptor is itself mechanistically informative\",\n      \"pmids\": [\"18753255\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"FGFR3 activation by FGF1 ligand in multiple myeloma KMS11 cells induces phosphorylation of tandem tyrosines in the kinase domain activation loop; mass spectrometry identified 52 proteins with pY sites sensitive to the FGFR3 inhibitor PD173074, including Syndecan-1/CD138, defining the FGFR3 phosphotyrosine signaling network.\",\n      \"method\": \"Label-free quantitative phosphoproteomic mass spectrometry, FGFR3 inhibitor treatment, pervanadate stimulation\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — systematic phosphoproteomic approach with inhibitor validation, identifies activation loop phosphorylation and network substrates in a disease-relevant cell line\",\n      \"pmids\": [\"19901323\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"FGFR3 is internalized by both clathrin-dependent and clathrin-independent/dynamin-independent mechanisms, unlike FGFR1 which relies predominantly on clathrin-mediated endocytosis; clathrin depletion only partially inhibits FGFR3 internalization and has minimal effect on FGFR3 degradation and signaling duration.\",\n      \"method\": \"Clathrin depletion, dominant-negative dynamin mutants, live-cell imaging, signaling assays (Western blot), comparison with FGFR1\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple perturbation approaches (clathrin depletion, dominant-negative dynamin, multiple proposed endocytic regulators) with functional readouts and mechanistic comparison\",\n      \"pmids\": [\"21779335\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"FGFR3 G380R (achondroplasia) transmembrane domain mutation causes the mutant receptor to form heterodimers with wild-type FGFR3 at lower probability than wild-type homodimers at low ligand concentrations, as demonstrated using a kinase-dead truncated FGFR3 construct that depletes the active receptor pool.\",\n      \"method\": \"Cell-based dimerization assay using truncated kinase-dead FGFR3 construct, phosphorylation assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — designed dominant-negative approach with quantitative phosphorylation readout, single lab\",\n      \"pmids\": [\"21324899\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"FGFR3 gain-of-function mutations cause abnormal membranous ossification in addition to endochondral ossification defects in achondroplasia: Fgfr3(Y367C/+) mice exhibit partial premature fusion of coronal sutures and non-ossified gaps in frontal bones, demonstrating that FGFR3 signaling affects both endochondral and membranous bone formation.\",\n      \"method\": \"Fgfr3(Y367C/+) knock-in mouse model, craniofacial morphological analysis, comparison with human ACH patient imaging\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic model with morphological readout, corroborated by patient data, single lab\",\n      \"pmids\": [\"24419316\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Activating Fgfr3 mutation (Y367C) in chondrocytes affects trabecular bone formation via a paracrine mechanism during growth: the bone formation defect (reduced trabecular bone volume and thickness, increased osteoclast recruitment, defective osteoblast mineralization) is only observed when the mutation is expressed in cartilage (not in mature osteoblasts), and primary osteoblast proliferation/differentiation is not directly affected by Fgfr3 activation.\",\n      \"method\": \"Three mouse models expressing Fgfr3(Y367C/+) ubiquitously, chondrocyte-specific, or osteoblast-specific; histomorphometry, osteoclast and osteoblast activity assays\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — three tissue-specific genetic models with multiple quantitative readouts clearly establishing paracrine (not direct osteoblast) mechanism\",\n      \"pmids\": [\"22367969\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"A 12-amino-acid peptide (P3: VSPPLTLGQLLS) identified by phage display binds specifically to the extracellular domain of FGFR3, inhibits FGFR3 tyrosine kinase activity and ERK/MAPK downstream signaling, promotes chondrogenic differentiation of ATDC5 cells, and reverses neonatal lethality and bone growth retardation in TDII mice.\",\n      \"method\": \"Phage display library screening with FGFR3 as bait, in vitro kinase inhibition assay, chondrogenic cell differentiation assay, mouse model (TDII) rescue experiment\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — phage display identification, in vitro kinase assay, cell differentiation assay, and in vivo rescue experiment in disease model, multiple orthogonal methods\",\n      \"pmids\": [\"23014564\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"The FGFR3-TACC3 fusion gene (from tandem duplication on 4p16.3) generates an oncogenic protein in glioblastoma that is tumorigenic, while wild-type FGFR3 overexpression is not; the fusion escapes miR-99a regulation via 3'-UTR deletion and promotes cell proliferation and tumor progression.\",\n      \"method\": \"Whole transcriptome sequencing, cell culture proliferation assays, mouse xenograft model, miRNA binding analysis\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — functional comparison of fusion vs. wild-type FGFR3, in vitro and in vivo xenograft experiments, miRNA regulation mechanism, multiple orthogonal methods\",\n      \"pmids\": [\"23298836\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"FGFR3 promotes degradation of BMP type I receptor (BMPR1a) through Smurf1-mediated ubiquitination, thereby inhibiting BMP signaling and chondrogenic differentiation; chondrocyte-specific deletion of Bmpr1a rescues the bone overgrowth in Fgfr3-deficient mice; this BMPR1a degradation occurs independently of FGFR3 tyrosine kinase activity.\",\n      \"method\": \"Genetic rescue (chondrocyte-specific Bmpr1a knockout in Fgfr3-null mice), in vitro chondrogenic differentiation assays, Smad phosphorylation assays, ubiquitination assay, mouse growth plate analysis\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis rescue experiment plus mechanistic biochemical assays (ubiquitination, Smad phosphorylation) in multiple experimental systems\",\n      \"pmids\": [\"24657641\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Statin treatment corrects degraded cartilage formation in iPSC-derived chondrocytes from thanatophoric dysplasia type I and achondroplasia patients, and rescues bone growth in ACH model mice, demonstrating that statins can pharmacologically counteract FGFR3 gain-of-function skeletal dysplasia phenotypes.\",\n      \"method\": \"Patient-specific iPSC differentiation to chondrocytes, ACH mouse model treatment, histological and molecular analysis\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — human iPSC disease model plus mouse model with functional bone growth readout, novel therapeutic mechanism established\",\n      \"pmids\": [\"25231866\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"The FGFR3 juxtamembrane (JM) domain stabilizes unliganded FGFR3 dimers in the membrane through receptor-receptor contacts; this stabilization is additive with the contribution of a pathogenic TM domain mutation, and requires the JM domain to be linked to the FGFR3 TM domain (not merely membrane-anchored).\",\n      \"method\": \"Quantitative FRET-based dimerization assay in cell membranes, deletion/chimeric constructs\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct biophysical measurement of dimer stability in membranes using FRET, single lab, multiple domain constructs\",\n      \"pmids\": [\"25688803\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"FGFR3 deficiency in chondrocytes leads to formation of chondroma-like lesions (enchondromas and osteochondromas) via decreased ERK activity and upregulation of Indian hedgehog (IHH) signaling; MEK inhibition increases Ihh expression, and IHH signaling inhibitor treatment reduces chondroma-like lesion occurrence in Fgfr3-deficient mice.\",\n      \"method\": \"Postnatal chondrocyte-specific Fgfr3 deletion mouse model, ERK activity assay, gene expression analysis, pharmacological rescue with IHH inhibitor and MEK inhibitor\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO with pharmacological epistasis rescue experiments establishing FGFR3→ERK→IHH pathway in chondrogenesis\",\n      \"pmids\": [\"26091072\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"The FGFR3-TACC3 fusion protein is constitutively phosphorylated at key activating FGFR3 tyrosine residues (shown by TiO2-LC-MS/MS phosphopeptide enrichment); the TACC3 coiled-coil domain drives constitutive phosphorylation and increased MAPK activation, cellular transformation, and IL3-independent proliferation; FGFR3 kinase activity (not TACC3 phospho-tyrosines) is essential for oncogenic effects; nuclear localization is driven by the TACC3 domain independently of kinase activity.\",\n      \"method\": \"TiO2-LC-MS/MS phosphopeptide analysis, kinase-dead K508R mutant, domain deletion constructs, NIH3T3 transformation assay, Ba/F3 IL3-independence assay, nuclear localization imaging\",\n      \"journal\": \"Molecular cancer research : MCR\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — mass spectrometry phosphoproteomics with mutagenesis, multiple functional assays, and localization experiments in one study\",\n      \"pmids\": [\"26869289\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"The FGFR3-TACC3 (F3-T3) fusion activates oxidative phosphorylation and mitochondrial biogenesis in cancer cells; F3-T3 phosphorylates the phosphopeptide PIN4 as an intermediate step, which triggers peroxisome biogenesis and new protein synthesis; this converges on PGC1α through production of intracellular reactive oxygen species, enabling mitochondrial respiration and tumor growth.\",\n      \"method\": \"Transcriptional clustering analysis, metabolic assays (oxidative phosphorylation), ROS measurements, phosphoproteomics (PIN4 phosphorylation), peroxisome biogenesis assays, PGC1α activity assays, sensitivity to oxidative metabolism inhibitors\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal metabolic and biochemical assays in human tumors and cell lines identifying a novel signaling axis (F3-T3→PIN4→peroxisome→ROS→PGC1α→mitochondria)\",\n      \"pmids\": [\"29323298\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"FGFR3 S249C mutation in urothelium suppresses acute inflammatory response (neutrophil influx) at early tumor initiation stages in response to the carcinogen OH-BBN, thereby promoting bladder tumor development; early neutrophil depletion phenocopies the FGFR3 mutation effect on later inflammatory and tumorigenic outcomes.\",\n      \"method\": \"Genetically engineered mice expressing FGFR3 S249C or K644E in urothelium, carcinogen treatment (OH-BBN), neutrophil depletion with anti-Ly6G antibody, histological and inflammatory analysis at multiple timepoints\",\n      \"journal\": \"The Journal of pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic model with pharmacological epistasis (neutrophil depletion), multiple timepoints, single lab\",\n      \"pmids\": [\"30043421\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"FGFR3 signaling induces a MAPK/ERK-mediated increase in ETV5 transcription factor levels, which in turn elevates TAZ (a Hippo pathway co-transcriptional regulator), causing loss of contact-inhibition of proliferation; ETV5 knockdown in FGFR3-mutant bladder cancer cells reduces proliferation and anchorage-independent growth.\",\n      \"method\": \"FGFR3 inhibition/activation in bladder cancer cell lines, siRNA knockdown of ETV5, Western blot for ETV5 and TAZ levels, proliferation and anchorage-independent growth assays, MAPK pathway analysis\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pathway epistasis via knockdown with functional readouts establishing FGFR3→ERK→ETV5→TAZ axis, single lab\",\n      \"pmids\": [\"30952872\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"FGFR3 signaling via the BMPR1a pathway promotes lymphatic endothelial cell (LEC) formation; FGFR3 deficiency in LECs leads to decreased lymphangiogenesis through a BMPR1a-pSmad1/5-dependent mechanism, exacerbating local inflammation and heterotopic ossification after trauma.\",\n      \"method\": \"Conditional Fgfr3 knockout in Col2+ cells and Prox1+ LECs, lineage tracing, HO mouse model (Achilles tenotomy), signaling analysis (pSmad1/5), FGF9 local administration rescue\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple conditional KO and lineage tracing approaches with pathway-level signaling readout, single lab\",\n      \"pmids\": [\"34282140\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"FGFR3Δ7-9 splice variant (lacking exons 7-9) directly interacts with and phosphorylates TET2 at Y1902, leading to ubiquitination and proteasome-mediated degradation of TET2, thereby reducing PTEN expression and activating AKT to promote hepatocellular carcinoma proliferation. Wild-type FGFR3 does not interact with TET2.\",\n      \"method\": \"Mass spectrometry, co-immunoprecipitation, in vitro phosphorylation assay (Y1902 site), phospho-deficient mutant (Y1902F), ubiquitination assay, in vitro and xenograft in vivo proliferation assays\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — mass spectrometry identification, co-IP validation, direct phosphorylation site mapping with mutagenesis (Y1902F), ubiquitination assay, in vivo rescue, multiple orthogonal methods\",\n      \"pmids\": [\"33097695\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"fgfr3 loss-of-function in zebrafish causes delay in osteoblast expansion and differentiation during skull vault development, together with changes in extracellular matrix, establishing FGFR3 as a positive regulator of osteogenesis in cranial membranous bone formation.\",\n      \"method\": \"Fgfr3 loss-of-function zebrafish (fgfr3lof/lof), in vivo imaging, single-cell RNA sequencing of osteoblast lineage\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic loss-of-function with in vivo imaging and single-cell transcriptomics, ortholog in zebrafish, single lab\",\n      \"pmids\": [\"32379366\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"FGFR3 overexpression in DDP-resistant ovarian cancer cells enhances cisplatin resistance by phosphorylating EGFR and thereby activating the PI3K/AKT pathway; FGFR3 silencing suppresses EGFR phosphorylation and PI3K/AKT activation and restores DDP sensitivity in vitro and in nude mouse xenografts.\",\n      \"method\": \"Co-expression analysis, siRNA knockdown, FGFR3 overexpression, Western blot for EGFR phosphorylation and PI3K/AKT, cell viability assays, nude mouse xenograft\",\n      \"journal\": \"Biochemical pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain-of-function and loss-of-function with downstream signaling readouts and in vivo validation, single lab\",\n      \"pmids\": [\"33794187\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"FGFR3 in periosteal cells (PCs) is required for terminal chondrocyte hypertrophy and cartilage-to-bone transformation during fracture healing; Fgfr3Y637C/+ PCs fail to undergo this transformation and cause pseudarthrosis/fibrocartilage, while transplantation of wild-type PCs rescues this defect.\",\n      \"method\": \"Conditional knock-in Fgfr3Y637C/+ (Prx1Cre), fracture model, periosteal cell transplantation, histological and lineage analysis\",\n      \"journal\": \"Stem cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional genetic model plus cell transplantation rescue experiment, single lab, clear phenotypic readout\",\n      \"pmids\": [\"32916123\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"FGFR3 is a receptor tyrosine kinase that signals through dimerization (stabilized by its transmembrane and juxtamembrane domains) and activation-loop tyrosine phosphorylation, activating downstream cascades including MAPK/ERK, STAT1/STAT3, PI3K/AKT, and PLC-γ; in cartilage it acts as a negative regulator of chondrocyte proliferation and differentiation by suppressing IHH and BMP signaling (promoting BMPR1a degradation via Smurf1-mediated ubiquitination), while in cancer settings gain-of-function mutations or oncogenic FGFR3-TACC3 fusions drive constitutive kinase activity, alternative metabolic reprogramming through the PIN4-peroxisome-ROS-PGC1α axis, and EGFR transphosphorylation, and FGFR3 is internalized via both clathrin-dependent and clathrin-independent mechanisms that modulate signaling duration.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"FGFR3 is a receptor tyrosine kinase that signals through ligand-induced or constitutive dimerization and activation-loop tyrosine phosphorylation to engage MAPK/ERK, STAT1/STAT3, PI3K, PLC-γ and Shp2 effectors [#2, #9]. Dimerization is stabilized by intracellular receptor-receptor contacts: the juxtamembrane domain stabilizes unliganded dimers when linked to the transmembrane segment, and transmembrane-domain mutations such as G375C/G380R promote ligand-independent dimerization and phosphorylation [#1, #11, #18]. In the developing skeleton FGFR3 acts as a negative regulator of chondrocyte proliferation and differentiation, signaling through ERK to suppress Indian hedgehog—its loss elevating IHH and producing chondroma-like lesions [#3, #19]—and inhibiting BMP signaling by driving Smurf1-mediated ubiquitination and degradation of the BMP type I receptor BMPR1a, a function independent of FGFR3 kinase activity [#16]. FGFR3 signaling also coordinates membranous ossification, synchondrosis closure, and the cartilage-to-bone transition during growth and fracture repair, acting in part through paracrine effects of mutant chondrocytes on osteoblasts and osteoclasts [#7, #13, #28]. Gain-of-function FGFR3 mutations cause achondroplasia and thanatophoric dysplasia, and extracellular-domain-targeting peptide inhibitors and statins reverse these skeletal phenotypes in disease models [#1, #14, #17]. In cancer, activating FGFR3 mutations substitute for Ras to drive MAPK signaling in urothelial carcinoma [#5], oncogenic FGFR3-TACC3 fusions confer constitutive kinase activity and metabolic reprogramming through a PIN4–peroxisome–ROS–PGC1α axis [#20, #21], and FGFR3 transphosphorylates EGFR to sustain PI3K/AKT signaling [#27]. FGFR3 is internalized by both clathrin-dependent and clathrin-independent routes, modulating signaling duration [#10].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Established that FGFR3 mutations are pleiotropic—affecting skin as well as the skeleton—when a transmembrane-domain substitution was found in Crouzon syndrome with acanthosis nigricans, broadening the disease scope of FGFR3 beyond dwarfism.\",\n      \"evidence\": \"Mutation analysis / DNA sequencing in unrelated patient families\",\n      \"pmids\": [\"7493034\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No functional reconstitution of the Ala391Glu allele\", \"Mechanism linking the receptor mutation to the skin phenotype unresolved\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Resolved how a transmembrane-domain mutation activates FGFR3 by showing G375C/G369C causes ligand-independent dimerization and phosphorylation, linking constitutive receptor activity to growth-plate disorganization and dwarfism in vivo.\",\n      \"evidence\": \"Biochemical dimerization/phosphorylation assays plus knock-in mouse with growth-plate histology\",\n      \"pmids\": [\"10587515\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not map the full downstream effector cascade\", \"Stat activation correlative within the model\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Defined the downstream signaling repertoire of activated FGFR3 by showing a constitutively active kinase-domain mutant engages Shp2, PLC-γ, MAPK, Stat1/Stat3 and PI3K and transforms cells, establishing the effector network.\",\n      \"evidence\": \"In vitro signaling assays, NIH3T3 transformation, PC12 neurite outgrowth with K650E mutant\",\n      \"pmids\": [\"10918587\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Effectors defined with a single hyperactive mutant\", \"Quantitative contribution of each pathway not dissected\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Provided a cellular mechanism for FGFR3-mediated inhibition of chondrocytes, showing the active receptor blocks proliferation and differentiation and alters integrin-dependent matrix preference.\",\n      \"evidence\": \"Stable expression of FGFR3Ach (G380R) in chondrocytic cells with proliferation, differentiation and apoptosis assays\",\n      \"pmids\": [\"10646125\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single cell line and lab\", \"Did not identify the transcriptional mediators of growth arrest\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Identified a CNS role for FGFR3 as a marker and repressor of astrocyte GFAP expression, extending its biology beyond cartilage.\",\n      \"evidence\": \"Fgfr3-null mouse with GFAP immunostaining of grey-matter astrocytes\",\n      \"pmids\": [\"12441294\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Downstream pathway controlling GFAP repression unknown\", \"Ligand driving astrocytic signaling not identified\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Placed FGFR3 firmly upstream of MAPK in tumorigenesis by demonstrating mutual exclusivity of FGFR3 and Ras mutations in urothelial carcinoma, implying both activate the same oncogenic pathway.\",\n      \"evidence\": \"Mutation screening of bladder tumours and cell lines with statistical epistasis analysis\",\n      \"pmids\": [\"15897885\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Correlative genetic epistasis, not functional\", \"Did not establish dependency of tumours on the pathway\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Revealed compartment-specific activation, showing intracellular-domain mutants are prematurely phosphorylated in the Golgi and impair receptor glycosylation, linking mutation class to subcellular signaling site.\",\n      \"evidence\": \"Transfection of FGFR3 mutant panel with phosphorylation/glycosylation Western blots\",\n      \"pmids\": [\"17320202\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of Golgi signaling for disease not established\", \"Single-lab cell-culture observation\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Systematically mapped the FGFR3 phosphotyrosine network in a disease cell context, identifying activation-loop tyrosines and 52 inhibitor-sensitive substrates including Syndecan-1.\",\n      \"evidence\": \"Label-free quantitative phosphoproteomics with FGFR3 inhibitor PD173074 in multiple myeloma cells\",\n      \"pmids\": [\"19901323\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct vs indirect substrates not all distinguished\", \"Functional role of individual network nodes untested\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Distinguished FGFR3 trafficking from FGFR1 by showing FGFR3 uses both clathrin-dependent and clathrin/dynamin-independent endocytosis, with internalization route shaping degradation and signaling duration.\",\n      \"evidence\": \"Clathrin depletion, dominant-negative dynamin, live imaging and signaling assays versus FGFR1\",\n      \"pmids\": [\"21779335\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular machinery of the clathrin-independent route not defined\", \"Link between trafficking and disease signaling unexplored\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Quantified the biophysical basis of the achondroplasia mutation, showing G380R alters heterodimerization probability with wild-type receptor at low ligand.\",\n      \"evidence\": \"Cell-based dimerization assay using a truncated kinase-dead FGFR3 construct\",\n      \"pmids\": [\"21324899\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Indirect measure via dominant-negative depletion\", \"Single lab\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Defined the skeletal output and physiological limits of FGFR3: it promotes synchondrosis closure and BMP-dependent ossification, but is not the principal renal mediator of FGF23 signaling, narrowing its endocrine role.\",\n      \"evidence\": \"Chondrocyte-specific Fgfr3 activation mice and Fgfr3/Fgfr4-null × Hyp crosses with histology and physiological readouts\",\n      \"pmids\": [\"18923003\", \"18753255\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct BMP target genes not all defined\", \"Redundancy among FGFRs in other tissues not fully mapped\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Dissected the cellular geography of skeletal disease by showing FGFR3 gain-of-function impairs both endochondral and membranous bone and acts on bone via a paracrine signal from cartilage rather than direct osteoblast effects.\",\n      \"evidence\": \"Ubiquitous, chondrocyte-specific and osteoblast-specific Fgfr3(Y367C) knock-in mice with histomorphometry\",\n      \"pmids\": [\"24419316\", \"22367969\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the paracrine signal to osteoblasts/osteoclasts not defined\", \"Mechanism of membranous defect unresolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Defined a bona fide oncogenic FGFR3 species by showing the FGFR3-TACC3 fusion, but not wild-type overexpression, is tumorigenic and escapes miR-99a regulation.\",\n      \"evidence\": \"Whole transcriptome sequencing, proliferation assays, xenografts and miRNA binding analysis in glioblastoma\",\n      \"pmids\": [\"23298836\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of constitutive activation not yet resolved in this study\", \"Downstream signaling of fusion not characterized here\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Established a kinase-independent FGFR3 function and a developmental regulatory node by showing FGFR3 drives Smurf1-mediated BMPR1a degradation to inhibit BMP signaling and chondrogenesis, with Bmpr1a deletion rescuing Fgfr3-null overgrowth.\",\n      \"evidence\": \"Genetic epistasis rescue, ubiquitination and Smad phosphorylation assays\",\n      \"pmids\": [\"24657641\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How FGFR3 recruits Smurf1 to BMPR1a not mechanistically resolved\", \"Relative weight of kinase-dependent vs -independent outputs in vivo unclear\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Demonstrated druggability of FGFR3 in skeletal disease via an extracellular-domain-binding peptide that inhibits kinase activity, promotes chondrogenesis and rescues TDII mice.\",\n      \"evidence\": \"Phage display, in vitro kinase inhibition, differentiation assay and in vivo TDII rescue\",\n      \"pmids\": [\"23014564\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Peptide pharmacology and selectivity not fully characterized\", \"Translational development beyond model not addressed\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identified a pharmacological corrective strategy by showing statins rescue cartilage and bone-growth phenotypes in patient iPSC chondrocytes and ACH mice.\",\n      \"evidence\": \"Patient iPSC-derived chondrocyte models and ACH mouse statin treatment\",\n      \"pmids\": [\"25231866\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular target linking statins to FGFR3 signaling not defined\", \"Long-term in vivo efficacy not assessed\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Resolved the dimer-stabilizing role of the juxtamembrane domain, showing it stabilizes unliganded FGFR3 dimers additively with a pathogenic TM mutation when tethered to the TM segment.\",\n      \"evidence\": \"Quantitative FRET dimerization assays with deletion/chimeric constructs\",\n      \"pmids\": [\"25688803\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural detail of JM-mediated contacts not defined\", \"Single biophysical lab\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Placed FGFR3 upstream of an ERK→IHH axis in cartilage homeostasis by showing Fgfr3 loss reduces ERK, derepresses IHH and causes chondromas, reversible by IHH or MEK inhibition.\",\n      \"evidence\": \"Postnatal chondrocyte-specific Fgfr3 deletion with ERK assays and pharmacological epistasis\",\n      \"pmids\": [\"26091072\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcriptional link between ERK and IHH not defined\", \"Relationship to BMPR1a pathway not integrated\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Explained how the FGFR3-TACC3 fusion is constitutively active, showing the TACC3 coiled-coil drives FGFR3 autophosphorylation and MAPK activation while FGFR3 kinase activity is essential for transformation and TACC3 drives nuclear localization.\",\n      \"evidence\": \"TiO2-LC-MS/MS phosphoproteomics, kinase-dead and domain-deletion mutants, transformation and localization assays\",\n      \"pmids\": [\"26869289\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Nuclear function of the fusion not defined\", \"In vivo relevance of nuclear localization untested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Uncovered a metabolic mechanism of FGFR3-TACC3 oncogenesis, showing the fusion phosphorylates PIN4 to trigger peroxisome biogenesis and ROS that converge on PGC1α to drive mitochondrial respiration and tumor growth.\",\n      \"evidence\": \"Transcriptional clustering, metabolic and ROS assays, phosphoproteomics and PGC1α activity assays in tumors and cell lines\",\n      \"pmids\": [\"29323298\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Generalizability beyond fusion-positive tumours unclear\", \"Direct PIN4-to-peroxisome signaling steps incomplete\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Linked FGFR3 mutation to tumour-promoting immune modulation, showing FGFR3 S249C suppresses early neutrophil influx during bladder carcinogenesis, with neutrophil depletion phenocopying the effect.\",\n      \"evidence\": \"FGFR3-mutant urothelium mice with carcinogen exposure and antibody-mediated neutrophil depletion\",\n      \"pmids\": [\"30043421\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular mediator of neutrophil suppression unknown\", \"Single carcinogen model\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Connected FGFR3 to contact-inhibition loss by defining an ERK→ETV5→TAZ axis driving proliferation in mutant bladder cancer.\",\n      \"evidence\": \"FGFR3 inhibition/activation and ETV5 knockdown with proliferation and anchorage-independent growth assays\",\n      \"pmids\": [\"30952872\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct binding of ETV5 to TAZ regulatory elements not shown\", \"In vivo validation absent\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Extended FGFR3 function to lymphatic biology, showing FGFR3 promotes lymphatic endothelial cell formation via BMPR1a–pSmad1/5 signaling, with loss exacerbating inflammation and heterotopic ossification.\",\n      \"evidence\": \"Conditional Fgfr3 knockout, lineage tracing and FGF9 rescue in a heterotopic ossification model\",\n      \"pmids\": [\"34282140\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cell-type-specific BMPR1a regulation versus chondrocyte degradation paradigm not reconciled\", \"Single lab\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identified an isoform-specific oncogenic mechanism, showing the FGFR3Δ7-9 splice variant phosphorylates TET2 at Y1902 to trigger its degradation, lowering PTEN and activating AKT in hepatocellular carcinoma, whereas wild-type FGFR3 does not bind TET2.\",\n      \"evidence\": \"Mass spectrometry, co-IP, phosphosite mapping (Y1902F), ubiquitination assay and xenografts\",\n      \"pmids\": [\"33097695\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Prevalence of this splice variant across tumours unclear\", \"Structural basis of variant-specific TET2 binding undefined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Established FGFR3 as a positive regulator of cranial osteogenesis, showing zebrafish fgfr3 loss delays osteoblast expansion and alters matrix during skull-vault formation, complementing mammalian membranous-bone phenotypes.\",\n      \"evidence\": \"fgfr3 loss-of-function zebrafish with in vivo imaging and single-cell RNA-seq\",\n      \"pmids\": [\"32379366\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Signaling pathway underlying osteoblast delay not defined\", \"Conservation of mechanism to mammals not directly tested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Defined a periosteal requirement for FGFR3 in fracture repair, showing mutant periosteal cells fail terminal chondrocyte hypertrophy and cartilage-to-bone transformation, rescuable by wild-type cell transplantation.\",\n      \"evidence\": \"Conditional Fgfr3Y637C knock-in fracture model with periosteal cell transplantation\",\n      \"pmids\": [\"32916123\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular block to hypertrophic transition not defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Revealed FGFR3 as a driver of therapy resistance via receptor cross-talk, showing FGFR3 transphosphorylates EGFR to activate PI3K/AKT and confer cisplatin resistance in ovarian cancer.\",\n      \"evidence\": \"FGFR3 overexpression/silencing with EGFR phosphorylation and PI3K/AKT readouts and xenografts\",\n      \"pmids\": [\"33794187\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs indirect EGFR transphosphorylation not resolved\", \"Single lab\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How FGFR3's kinase-dependent (MAPK/ERK, STAT, PI3K) and kinase-independent (Smurf1-BMPR1a) outputs are integrated to set the balance between chondrocyte suppression, osteogenic promotion, and oncogenic signaling across tissues remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking endocytic route, signaling duration and pathway choice\", \"Mechanism of context-dependent positive vs negative skeletal effects unexplained\", \"Recruitment logic of Smurf1 and substrate selection by mutant/fusion forms undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [2, 9, 20, 25, 27]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [1, 2, 9, 25]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [1, 2, 11, 18]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [23]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [10, 11, 18]},\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [6]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [20]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [2, 9, 23, 27]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [7, 13, 16, 19, 26, 28]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [5, 15, 20, 21, 25]},\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [10]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [21]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"BMPR1a\", \"Smurf1\", \"TACC3\", \"PIN4\", \"TET2\", \"EGFR\", \"SDC1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}